Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.61 |
| ▸ | PTH1R | Q03431 | 4/20 | 0.61 |
| ▸ | GLP1R | P43220 | 13/20 | 0.59 |
| ▸ | IL23R | Q5VWK5 | 1/20 | 0.56 |
| ▸ | NR3C1 | P04150 | 1/20 | 0.56 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30038811 | 0.92 | RXFP1 (0.72) | RXFP1PTH1RGLP1RIL23R | |
| SCHEMBL30978207 | 0.90 | GLP1R (0.60) | RXFP1PTH1RGLP1R | |
| SCHEMBL30271992 | 0.89 | RXFP1 (0.68) | RXFP1PTH1RGLP1R | |
| SCHEMBL30183209 | 0.89 | RXFP1 (0.68) | RXFP1PTH1RGLP1R | |
| SCHEMBL30844669 | 0.89 | RXFP1 (0.69) | RXFP1PTH1RGLP1R | |
| SCHEMBL31686944 | 0.89 | RXFP1 (0.68) | RXFP1PTH1RGLP1R | |
| SCHEMBL29663916 | 0.88 | PTH1R (0.59) | RXFP1PTH1RGLP1R | |
| SCHEMBL30874405 | 0.87 | RXFP1 (0.64) | RXFP1PTH1RGLP1R | |
| SCHEMBL29359687 | 0.87 | PTH1R (0.66) | RXFP1PTH1RGLP1RIL23RNR3C1 | |
| SCHEMBL16705802 | 0.86 | RXFP1 (0.55) | RXFP1PTH1RGLP1RIL23R |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8017633-B2 | Administering [3-cyclopropylmethoxy-4-difluoromethoxy-N-(3,5-dichloropyrid-4-yl)benzamide; hypertension, hyperlipidemia, hyperuricemia, gout and hypercoagulability | NYCOMED GMBH (DE) | 2011-09-13 | — | — | US | disclosed |
| US-20080214625-A1 | Roflumilast for the Treatment of Diabetes Mellitus | KONINKLIJKE HILIPS ELECTRONICS, N.V. (NL) | 2008-09-04 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080214625-A1 | Roflumilast for the Treatment of Diabetes Mellitus | NOS3, PLAT, PTGIS | RXFP1 30/4885PTH1R 978/4885GLP1R 46/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.